GO
Loading...

Amgen Inc

More

  • April 4- Amgen Inc said its experimental drug to treat a deadly form of skin cancer shrank tumors, but did not significantly improve overall survival rates in patients enrolled in a late-stage study.

  • April 3- Amgen Inc said it would end an agreement with GlaxoSmithKline Plc for the marketing of its osteoporosis drug in some regions outside the United States. Amgen said it would take over the marketing of the drug, sold under the brand name Prolia, in most areas under the agreement, including the European Union, Switzerland, Norway, Russia and Mexico, by Dec. 31.

  • April 3- Amgen Inc said it was ending an agreement with GlaxoSmithKline Plc, under which the British company marketed Amgen's postmenopausal osteoporosis drug in some regions outside the United States.

  • Stocks wrapped up the session on a high note, with the Dow logging triple-digit gains, after Federal Reserve Chair Janet Yellen said there's still room for the central bank to help the economy. But major index ended relatively flat for the first quarter.

  • FTI Consulting managing director Barbara Ryan provides insight on new drugs showing dramatic improvement in the standard of care for high cholesterol.

  • New class of cholesterol drugs     Monday, 31 Mar 2014 | 1:19 PM ET

    CNBC's Dominic Chu reports on news out about a special new drug that could combat cholesterol.

  • Midday Movers: Amgen, Biogen, Priceline & More Monday, 31 Mar 2014 | 12:18 PM ET

    Take a look at some of Monday's midday movers:

  • Merck, Glaxo end co-pay assistance for Obamacare plans Wednesday, 26 Mar 2014 | 6:26 PM ET

    March 26- Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.

  • ZURICH, March 22- Results of two late-stage clinical trials showed high efficacy for Novartis' drug secukinumab when used by patients suffering from moderate-to-severe plaque psoriasis, the Swiss drugmaker said on Saturday.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.

  • March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • WASHINGTON, March 4- In a case eagerly watched by publicly traded companies regularly sued by investors, the U.S. Supreme Court will on Wednesday consider overruling a 26- year-old precedent that made it easier for plaintiffs to negotiate large class action settlements.

  • Feb 5- Merck& Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but shares rose 1.5 percent on enthusiasm for newly announced cancer-drug partnerships with rival U.S. companies.

  • Cheaper generics hit Merck fourth-quarter profit Wednesday, 5 Feb 2014 | 8:36 AM ET
    Merck sign in front of the company's building on October 2, 2013 in Summit, New Jersey.

    Merck reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.

  • Feb 5- Merck& Co Inc reported quarterly sales that were slightly lower than expected, hurt by competition from cheaper generic medicines, and predicted full-year earnings at the lower end of analysts' expectations. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter.

  • Early movers: DOW, BA, WLP, T, YHOO, EA, & more Wednesday, 29 Jan 2014 | 8:07 AM ET
    Traders on the floor of the New York Stock Exchange on Tuesday.

    Some of the names on the move ahead of the open.

  • Jan 28- Amgen Inc on Tuesday reported a quarterly profit that beat Wall Street forecasts, as it gained full control of its blockbuster rheumatoid arthritis drug Enbrel and saw solid growth in sales of newer products.

Most Popular Video

Thursday, 17 Apr 2014 | 5:00 AM ET

Today is CNBC's 25th anniversary. There have been a lot of great moments in the network's history. Here are just a few.

Thursday, 17 Apr 2014 | 3:15 AM ET

Jonny Forsyth, global drinks analyst at Mintel, says China has been a "cash cow" for drink-makers, but the slowdown is having a big impact on sales.

Thursday, 17 Apr 2014 | 1:35 AM ET

CNBC's Helia Ebrahimi discusses the Co-Operative's troubled story from drug buying allegations against the former chairman, to big financial black holes.